About ALung
ALung is a company based in Pittsburgh (United States) founded in 1997 was acquired by LivaNova in May 2022. ALung has raised $132.56 million across 23 funding rounds from investors including UPMC, Abiomed and LivaNova. ALung offers products and services including Essenz™ Perfusion System, VNS Therapy™ for Epilepsy, and VNS Therapy™ for Depression. ALung operates in a competitive market with competitors including Belluscura, Lungpacer, hemovent, OneBreath and Brio Device, among others.
- Headquarter Pittsburgh, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Livanova Plc
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ALung
ALung offers a comprehensive portfolio of products and services, including Essenz™ Perfusion System, VNS Therapy™ for Epilepsy, and VNS Therapy™ for Depression.
System for cardiopulmonary support during surgeries
Implantable device to treat drug-resistant epilepsy
Device for managing difficult-to-treat depression symptoms
People of ALung
Unlock access to complete
Unlock access to complete
Funding Insights of ALung
ALung has successfully raised a total of $132.56M across 23 strategic funding rounds. The most recent funding activity was a Series C round of $1.81 million completed in May 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ALung
ALung has secured backing from 14 investors, including institutional and venture fund investors. Prominent investors backing the company include UPMC, Abiomed and LivaNova.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Venture capital is provided to high-potential tech companies in the Midwest.
|
Locked | Locked | Locked | |
|
US focused early-stage VC firm investing in tech & life sciences start-ups
|
Locked | Locked | Locked |
Investor details for ALung
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ALung
Investment portfolio details for ALung
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ALung
Detailed financials for ALung
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Alung Comparisons
Peer comparison for ALung
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ALung
ALung operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Belluscura, Lungpacer, hemovent, OneBreath and Brio Device, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of medical devices for laparoscopic procedures
|
|
| Locked | Locked | Locked |
Neurostimulation-based pacer for diaphragm strength is developed.
|
|
| Locked | Locked | Locked |
Equipment for extracorporeal life support and CO2 removal is developed.
|
|
| Locked | Locked | Locked |
Portable mechanical ventilators for intensive care patients are developed.
|
|
| Locked | Locked | Locked |
Medical devices for emergency airway management are developed.
|
Detailed competitors of ALung
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Alung
Complete news archive for ALung
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ALung
ALung was founded in 1997 and raised its 1st funding round 5 years after it was founded.
ALung is headquartered in Pittsburgh, United States. It is registered at Pittsburgh, Pennsylvania, United States.
ALung is a funded company, having raised a total of $132.56M across 23 funding rounds to date.
ALung was founded in 1997 in Pittsburgh, United States, and operates within the medical technology sector. Extracorporeal CO2 removal systems are developed to support mechanical ventilation for patients. The Hemolung Cartridge is integrated with a centrifugal blood pump and gas exchange membrane as a single device. Focus is placed on respiratory assistance technologies, with headquarters maintained in Pittsburgh.
ALung's top competitors include Belluscura, Lungpacer and hemovent.
ALung offers Essenz™ Perfusion System, VNS Therapy™ for Epilepsy, and VNS Therapy™ for Depression.
ALung has 14 investors. Key investors include UPMC, Abiomed, LivaNova, West Capital Advisors, and Pittsburgh Life Sciences Greenhouse.